{"changeSha256":"aa5f953b96e6f073feff4c27e466345bd95e9f8c5ce36f2ed37e5d15c02844fd","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Mounjaro and Zepbound","before":"U.S. label record","field":"Status"},{"after":"A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.","before":"A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.","field":"Profile summary"},{"after":"The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.","before":"The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2","before":"dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]; U.S. Food and Drug Administration [sources: fda-mounjaro-s044-s045-approval-2026, fda-unapproved-glp1-concerns-2026-r2]","before":"U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]","field":"Named organizations"},{"after":"name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-unapproved-glp1-concerns-2026-r2","before":"name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tirzepatide/versions/5/","version":5},"id":"profile:tirzepatide:v5","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026).","peptideSlugs":["tirzepatide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/tirzepatide/v4.json","sha256":"cd1b5296aabbc561fc1d69eb1fa150387ec6667cb1a85f409e83dfe89c58536d"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/tirzepatide/versions/4/","version":4},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-mounjaro-s044-s045-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044,215866Orig1s045ltr.pdf","verifiedAt":"2026-11-14"},{"id":"fda-zepbound-s041-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s041correctedltr.pdf","verifiedAt":"2026-11-14"},{"id":"fda-unapproved-glp1-concerns-2026-r2","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026","url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","verifiedAt":"2026-11-14"}],"subject":{"slug":"tirzepatide","type":"profile"}}
